More than half the £101m spend has been on legal fees – including bringing in external lawyers.
Nature, Published online: 24 February 2026; doi:10.1038/s41586-026-10294-0
。关于这个话题，爱思助手下载最新版本提供了深入分析
Global news & analysis
Version: 42.20250921.0 (2025-09-21T19:04:38Z)
但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。